Avaí Bio and Austrianova present Klothonova encapsulated-cell data
Avaí Bio and its joint venture partner Austrianova used the Second Annual Klotho Conference in Miami to present an update on Klothonova, their 50/50 venture developing implanted, encapsulated cells designed to produce α-Klotho continuously over the long term. The programme remains at a preclinical stage.
Prof. Walter H. Günzburg, co-founder and chief technology officer of Austrianova, delivered the 20-minute presentation on behalf of all three entities. He described how Austrianova's proprietary Cell-in-a-Box technology is being applied to engineer a cell line that overexpresses α-Klotho, with the cells enclosed in a protective capsule intended to shield them from immune rejection while allowing sustained protein secretion. The approach is designed to avoid the need for repeated dosing of the protein itself.
"Cell encapsulation is intended to turn a living cell line into a durable delivery system," Prof. Günzburg said. "Our objective with Klothonova is to evaluate whether encapsulated cells can provide a more sustained source of α-Klotho than repeated dosing of the protein itself."
Avaí Bio and Austrianova have previously reported completion of a GMP-grade master cell bank of the genetically modified cells, along with adventitious-agent and viral testing and the establishment of a working cell bank to support further process development. The companies did not announce any in vivo efficacy data, IND-enabling study timelines, or a named therapeutic indication in materials accompanying the conference presentation.
The α-Klotho opportunity
α-Klotho is a pleiotropic protein with roles in ageing, kidney function, and metabolic regulation. Interest in the protein as a therapeutic target has grown substantially over the past decade, driven in part by epidemiological data linking low Klotho levels to age-related decline across multiple organ systems. The Second Annual Klotho Conference, co-chaired by Dr. Carmela R. Abraham and Howard J. Leonhardt, drew researchers, clinicians, investors, and members of the broader longevity community; the keynote was delivered by Dr. Makoto Kuro-o, who first identified Klotho in 1997.
Several academic groups and a number of early-stage companies are investigating approaches to Klotho augmentation, including recombinant protein delivery, gene therapy vectors, and small-molecule upregulators. The cell-encapsulation route pursued by Klothonova sits in a less crowded part of the landscape, with the principal advantage claimed being durability of delivery without repeat administration.
Competitive and regulatory context
Cell encapsulation as a drug-delivery modality has a longer clinical history in other areas, most notably in the treatment of amyotrophic lateral sclerosis and certain ocular conditions, though no encapsulated-cell product has yet reached widespread commercial approval. Regulatory agencies including the FDA and EMA treat encapsulated cell therapies as combination products or advanced therapy medicinal products, which typically imposes a more complex and lengthy approval pathway than conventional biologics.
For Avaí Bio, an OTCQB-listed emerging biotech with a stated focus on genetically modified cell lines and licensing partnerships, the Klothonova venture represents the primary disclosed asset. Investors tracking the company will look for the first in vivo dataset, a defined indication, and any indication of a clinical development timeline as the near-term milestones that would meaningfully de-risk the programme.